Mesoblast reports financial results and operational highlights for the period ended september 30, 2022

Durable long-term survival outcomes through 4 years for children with steroid-refractory graft versus host disease (sr-agvhd) treated with remestemcel-l

MESO Ratings Summary

MESO Quant Ranking